secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001193125-24-260425
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio reports positive CABA-201 data at ACR 2024; all 8 patients drug-free responses
--------------------------------------------------------------------------------

- Eight patients dosed across RESET-Myositis, -SLE, -SSc trials; all off immunosuppressants through follow-up.
- Favorable safety: no ICANS (except one prior LN case); low-grade CRS in 3/8, no tocilizumab needed.
- Complete B cell depletion by day 22; transitional naïve B cell repopulation as early as 8 weeks in first 2 patients.
- All 4 SLE patients showed clinical responses; LN patient proteinuria improved >90%. DM patient achieved major TIS response and normal muscle strength.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524260425/0001193125-24-260425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524260425/d874885d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-260425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer